BSE filing, NSE: AKI. Summary written from the filing by ALFA Finder's alert engine.
Aki India Ltd: key numbers
- Share price
- ₹5.19
- Market cap
- ₹53.56 Cr
- Revenue (annual)
- ₹107.3 Cr
- Net profit (annual)
- ₹1.93 Cr
- P/E (TTM)
- 17.9×Sector 49.5×
- Promoter holding
- 54.02%+0.10% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Aki India Ltd
All →Aki India Annual General Meeting
AKI India Limited held its 32nd Annual General Meeting on September 23, 2026. The meeting discussed adoption of financial statements and various board appointments.
Aki India Price Movement Clarification
AKI India responded to an exchange surveillance query on significant price movement. The company stated it has no undisclosed price-sensitive information and attributed volatility to natural market forces.
Aki India Promoter Buying (Off-Market)
Promoter Asad Kamal Iraqi acquired 1,00,000 equity shares (0.10%) of AKI India Limited. This off-market transaction increased the promoter's total holding to 39.51%.
- Promoter stake change
- +0.10%
Aki India Promoter Buying (Off-Market): ₹0.1 Cr
Promoter Asad Kamal Iraqi acquired 100,000 equity shares of AKI India Ltd in an off-market transaction, increasing his stake from 39.41% to 39.51%.
- Value
- ₹0.10 Cr
- Promoter stake change
- +0.10%
Aki India Annual General Meeting
AKI India Ltd submitted its 32nd Annual Report for the financial year 2025-26. The Annual General Meeting is scheduled for September 23, 2026.
Aki India Board Meeting Outcome
Aki India Ltd's board meeting resulted in the approval of the 32nd AGM notice and a recommendation for material related party transactions.
Other other announcement announcements
All →eMudhra Other Announcement
eMudhra Ltd disclosed that SES ESG revised its ESG score from 68.0 to 64.9 in its ESG Report 2026. The company states it did not engage SES ESG, and the revision relates to its certificate business.
Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Sagarsoft (India) Other Announcement
Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.
Sadhana Nitro Chem Other Announcement
Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.
Shriram Asset Management Company Other Announcement
Shriram AMC filed ICRA's quarterly monitoring agency report on preferential issue proceeds. Utilisation is in line with the offer objects, with no deviation reported.
Jhandewalas Foods Other Announcement
Jhandewalas Foods filed its quarterly shareholding pattern for the period ended September 30, 2026. The filing records holdings by category and contains no transaction or money event.